Alembic Share Price

    103.72
    +1.92 (1.89%)
    ALEMBICLTD • 02 Sep, 2025 | 03:29 PM
    Buy
    with MTF at2.86xleverage

    1Y Annualised Return

    -35.59%

    3Y Annualised Return

    12.31%

    5Y Annualised Return

    4.02%

    10Y Annualised Return

    12.11%

    The current prices are delayed, login or Open Demat Account for live prices.

    Alembic Stock Performance

    1W Return0.08
    1Y Return-32.75
    Today's Low101.62
    Prev. Close101.80
    Mkt Cap (Cr.)2,663.34
    1M Return-6.74
    3Y Return41.69
    52-Week High166.75
    Open102.00
    PE Ratio18.72
    6M Return16.57
    Today's High104.86
    52-Week Low85.46
    Face Value2

    Alembic Company background

    Founded in: 1907
    Managing director: Malika C Amin
    Alembic Limited is one of the Indias most experienced manufactures of bulk drugs and pharmaceuticals formulation in human and animal healthcare. The Company operates primarily in the manufacture of Bulk Drugs and Real Estate Business. The company manufacture pharmaceuticals and chemicals, bulk drugs (penicillin and other antibiotics) and formulations. It works manufacturing facilities at Vadodara in Gujarat and Solan in Himachal Pradesh.Alembic Limited was incorporated in year 1907 with the name Alembic Chemical Works Company Limited in Vadodara to manufacture tinctures and alcohol. The name of the Company was changed to Alembic Limited in August, 1999. The Company started to manufacture cough syrup, vitamins, tonics and sulphur durgs in 1940. In 1961, it inaugurated the Pencillin Palnt. In 1968, it started to manufacture Streptomycin.In the 1971, they manufactured Erythromycin using expertise from Eli Lilly, USA and in the year 1972, they launched Althrocin, a brand of Erythromycin. In year 1997, Althrocin become top selling brand in India. In the year 2001, they started to manufacture Cephalosporin C. In June 2001, the company formed a wholly owned subsidiary company named Alembic Europe Pvt Ltd in UK.In the year 2005, the company has launched ZERO, a new generation, no calories, Sucralose Based Sugar Substitute which gave entry for the company into the highgrowth lifestyle OTC product segment. In May 2005, the generic alliances and API division were merged to form an independent SBU.The company has set up a formulation manufacturing facility at Baddi in Himachal Pradesh with a production capacity 900 million tablets and 600 million liquid oral bottles annually. During the year 200506, the company has increased the installed capacity of Tablets Capsules and Oral Preparation Ointments by 595 Million Nos and 720 MT respectively.During the year 200506, the company acquired API Plant at Karakhadi in Vadodara. In the year 2007, the company acquired the NonOncology Business of Dabur Pharma Ltd. Also in the same year, they entered into a licensing agreement for its Novel Drug Delivery Platform for Keppra XR with UCB Belgium. During the year 200708, the company acquired the API manufacturing facility of Nirayu Pvt Ltd at Panelav near Vododara.The Company formed a wholly owned subsidiary viz. Alembic Global Holding SA in Neuchatel, Switzerland in 2009. The Pharmaceutical Undertaking of the Company demerged and the same got transferred to Alembic Pharmaceuticals Limited with effect from Appointed date i.e. 1st April, 2010. The maiden real estate project Samsara was completed in 2014. The Company launched second real estate project, VEDA in 201516. It further launched two APIs in 2017. During year 201718, Alembic City Limited (formerly known as Alembic Exports Limited) became whollyowned subsidiary of the Company.During 201819, the Composite Scheme of Arrangement comprising of transfer and vesting of the Identified Real Estate Undertaking of Alembic Limited (the Company / the First Demerged Company) into Shreno Limited (the First Transferee Company/ the Second Demerged Company) and transfer and vesting of Engineering Division and Investment Division of Shreno Limited into Nirayu Private Limited (the Second Transferee Company) and their respective shareholders with effect from the Appointed Date i.e. 1st November, 2018 was sanctioned by the Honble National Company Law Tribunal, Ahmedabad Bench (NCLT) vide its order dated 26th July, 2019. Accordingly, Scheme was made effective from 26th July, 2019.The Company launched a residential project VEDA II during 2020. In FY 2025, VEDAII, one of the Companys gated community project has been completed in FY 2025. The Companys upscale premium residential projects, Townhouse24 also achieved 100% sales during the year. Other premium projects like The Villas and The Gardens witnessed decent demand. The Company also launched another housing project with 3BHK and 4BHK configurations called The Park Crescent.

    Alembic Financial Highlights


    Alembic reported a Q1 FY 2025-26 revenue of ₹49.75 crore, up 39.8% YoY, with net profit increased 55.7% to ₹17.81 crore. For the full year FY2025–2026, revenue reached ₹296.78 crore and profit touched at ₹144.57 crore.

    As of 02 Sep, 2025, Alembic share price is ₹103.7. The stock opened at ₹102 and had closed at ₹101.8 the previous day. During today’s trading session, Alembic share price moved between ₹101.62 and ₹104.86, with an average price for the day of ₹103.24. Over the last 52 weeks, the stock has recorded a low of ₹85.46 and a high of ₹166.75. In terms of performance, Alembic share price has increased by 13.9% over the past six months and has declined by 35.59% over the last year.
    Read More
    Alembic SIP Return Calculator

    Over the past

    1 year
    3 years
    5 years
    Total Investment of ₹65,00,000
    Would have become ₹54,64,784 (-15.93%)
    Daily SIP of 25,000 would have become 54,64,784 in 1 year with a gain of -10,35,215 (-15.93%)
    View details of Market Depth

    Alembic Fundamental

    Market Cap (in crs)

    2,663.34

    Face Value

    2

    Turnover (in lacs)

    258.23

    Key Metrics

    Qtr Change %
    37.80% Fall from 52W High
    -8.5
    Dividend yield 1yr %
    High in industry
    2.3

    Alembic Key Financials

    View more
    Loading chart...
    Loading chart...
    Loading chart...
    Loading chart...
    Alembic Quarterly Revenue
    Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024
    49.75 Cr
    60.27 Cr
    57.92 Cr
    52.91 Cr
    50.78 Cr
    Alembic Yearly Revenue
    Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
    296.78 Cr
    212.26 Cr
    191.51 Cr
    167.4 Cr
    83.79 Cr
    167.33 Cr
    Alembic Quarterly Net Profit/Loss
    Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024
    17.81 Cr
    23.75 Cr
    26.09 Cr
    77.31 Cr
    17.42 Cr
    Alembic Yearly Net Profit/Loss
    Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
    144.57 Cr
    92.87 Cr
    80.62 Cr
    86.19 Cr
    13.84 Cr
    93.03 Cr

    Alembic Result Highlights

    • Alembic Ltd reported a 4.4% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Jun (Q1 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 1.1%.

    • Its expenses for the quarter were up by 24.9% QoQ and 0.5% YoY.

    • The net profit decreased 14.6% QoQ and increased 10.4% YoY.

    • The earnings per share (EPS) of Alembic Ltd stood at 2.4 during Q1 FY 2025-26.

      Read more

    Data Source: BSE, Company announcements

    The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

    Alembic Shareholding Pattern

    Promoter
    70.9%
    Foreign Institutions
    1.5%
    Domestic Institutions
    0.1%
    Public
    27.6%
    Promoter
    70.9%
    Foreign Institutions
    1.6%
    Domestic Institutions
    0.1%
    Public
    27.4%
    Promoter
    70.9%
    Foreign Institutions
    1.8%
    Public
    27.3%
    Promoter
    70.9%
    Foreign Institutions
    2%
    Domestic Institutions
    0.1%
    Public
    27.1%
    Promoter
    70.9%
    Foreign Institutions
    1.4%
    Domestic Institutions
    0.1%
    Public
    27.6%
    Promoter
    70.9%
    Foreign Institutions
    1.1%
    Public
    28%

    Alembic Technical Analysis

    Moving Averages Analysis
    103.72
    Current Price
    Bullish Moving Averages
    2
    Bearish Moving Averages
    14
    5Day EMA
    103.00
    10Day EMA
    104.20
    12Day EMA
    104.60
    20Day EMA
    106.50
    26Day EMA
    107.60
    50Day EMA
    109.70
    100Day EMA
    110.80
    200Day EMA
    112.60
    5Day SMA
    102.40
    10Day SMA
    104.60
    20Day SMA
    106.50
    30Day SMA
    109.40
    50Day SMA
    112.80
    100Day SMA
    110.10
    150Day SMA
    107.40
    200Day SMA
    113.60
    Delivery & Volume
    Loading chart...

    Delivery & Volume

    PeriodCombined Delivery VolumeNSE+BSE Traded Volume
    Day Rs
    115207 Rs
    257947 Rs
    Week Rs
    152256 Rs
    291011 Rs
    Month Rs
    138009 Rs
    291349 Rs
    103.40
    Pivot
    Resistance
    First Resistance
    105.18
    Second Resistance
    106.64
    Third Resistance
    108.42
    Support
    First Support
    101.94
    Second support
    100.16
    Third Support
    98.70
    Relative Strength Index
    38.40
    Money Flow Index
    51.49
    MACD
    -2.92
    MACD Signal
    -2.71
    Average True Range
    2.68
    Average Directional Index
    29.39
    Rate of Change (21)
    -7.49
    Rate of Change (125)
    8.90

    Alembic Latest News

    20 AUG 2025 | Wednesday

    Alembic Ltd - 506235 - Announcement under Regulation 30 (LODR)-Newspaper Publication

    19 AUG 2025 | Tuesday

    Alembic Ltd - 506235 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot

    18 AUG 2025 | Monday

    Alembic gets USFDA nod for generic drug for skin condition

    View More

    Alembic Share Price FAQs

    Alembic share price is ₹103.72 in NSE and ₹103.7 in BSE as on 2/9/2025.

    Alembic share price in the past 1-year return was -32.74. The Alembic share hit a 1-year low of Rs. 85.46 and a 1-year high of Rs. 166.75.

    The market cap of Alembic is Rs. 2663.34 Cr. as of 2/9/2025.

    The PE ratios of Alembic is 18.72 as of 2/9/2025.

    The PB ratios of Alembic is 3.12 as of 2/9/2025

    You can easily buy Alembic shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

    The 52-week high and low of Alembic share price is ₹166.75 and ₹85.46 as of 2/9/2025.

    The earnings per share (EPS) of Alembic stood at 2.4 during Q1 FY 2025-26.

    Please be aware that Alembic stock prices are subject to continuous fluctuations due to various factors.

    Open Demat Account
    +91 -

    Popular Stocks
    0.00
    0.00 (0.00%)
    0.00
    0.00 (0.00%)
    0.00
    0.00 (0.00%)
    0.00
    0.00 (0.00%)
    0.00
    0.00 (0.00%)
    0.00
    0.00 (0.00%)
    0.00
    0.00 (0.00%)
    0.00
    0.00 (0.00%)
    0.00
    0.00 (0.00%)
    0.00
    0.00 (0.00%)
    Top Gainers
    286.70
    +6.85 (+2.45%)
    1,100.80
    +25.10 (+2.33%)
    1,200.90
    +26.50 (+2.26%)
    336.30
    +5.60 (+1.69%)
    158.39
    +2.22 (+1.42%)
    Top Losers
    3,234.50
    -80.90 (-2.44%)
    1,253.70
    -26.20 (-2.05%)
    1,942.50
    -26.10 (-1.33%)
    1,394.20
    -16.80 (-1.19%)
    2,540.00
    -30.20 (-1.18%)
    Open Demat Account
    +91 -